Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127

1.

Cancer drugs in the United States: Justum Pretium--the just price.

Kantarjian HM, Fojo T, Mathisen M, Zwelling LA.

J Clin Oncol. 2013 Oct 1;31(28):3600-4. doi: 10.1200/JCO.2013.49.1845. Epub 2013 May 6. No abstract available. Erratum in: J Clin Oncol. 2015 Oct 20;33(30):3523.

2.

The Karabus affair speaks to larger issues for American academic and medical centers.

Zwelling LA, Kurzrock R, Cohen PR, Levin B, Parish LC.

Clin Dermatol. 2013 May-Jun;31(3):325-6. doi: 10.1016/j.clindermatol.2013.03.001. No abstract available.

PMID:
23608452
3.

The anticipated and unintended consequences of the patient protection and affordable care act on cancer research.

Edge SB, Zwelling LA, Hohn DC.

Cancer J. 2010 Nov-Dec;16(6):606-13. doi: 10.1097/PPO.0b013e318201fdac. Review.

PMID:
21131793
4.

Evaluating quality in clinical cancer research: the M.D. Anderson Cancer Center experience.

Cox JD, Giralt SA, Veazie ML, Ajani JA, Bruner JM, Chan KW, Hittelman WN, Hunt KK, Iyer RB, Karp DD, Kuban DA, Lippman SM, Raad II, Rodriguez-Bigas MA, Zwelling LA, Markman M.

Oncology. 2009;77(2):75-81. doi: 10.1159/000226772. Epub 2009 Jul 1.

5.

Strategies for the administration of a clinical trials infrastructure: lessons from a comprehensive cancer center.

Zwelling LA, Brunelli CA.

Cancer Treat Res. 2007;132:241-74. Review. No abstract available.

PMID:
17305027
6.
7.

Interleukin-1 alpha increases the cytotoxic activity of etoposide against human osteosarcoma cells.

Jia SF, Zwelling LA, McWatters A, An T, Kleinerman ES.

J Exp Ther Oncol. 2002 Jan-Feb;2(1):27-36.

PMID:
12415617
8.
9.

Protecting the privacy of family members in research.

Brunelli CA, Zwelling LA.

JAMA. 2001 Apr 18;285(15):1961; author reply 1962-3. No abstract available.

PMID:
11308426
10.

Drug-induced cytotoxicity in tissue culture.

Herzog CE, Zwelling LA.

Methods Mol Biol. 2001;95:205-13. No abstract available.

PMID:
11089233
11.

Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells.

Zhou Z, Zwelling LA, Kawakami Y, An T, Kobayashi K, Herzog C, Kleinerman ES.

Cancer Res. 1999 Sep 15;59(18):4618-24.

12.

Absence of topoisomerase IIbeta in an amsacrine-resistant human leukemia cell line with mutant topoisomerase IIalpha.

Herzog CE, Holmes KA, Tuschong LM, Ganapathi R, Zwelling LA.

Cancer Res. 1998 Dec 1;58(23):5298-300.

13.

Topoisomerase II and the response to antileukemic therapy.

Kaufmann SH, Gore SD, Miller CB, Jones RJ, Zwelling LA, Schneider E, Burke PJ, Karp JE.

Leuk Lymphoma. 1998 Apr;29(3-4):217-37. Review.

PMID:
9684921
14.

Evaluation of a potential regulatory role for inverted CCAAT boxes in the human topoisomerase II alpha promoter.

Herzog CE, Zwelling LA.

Biochem Biophys Res Commun. 1997 Mar 27;232(3):608-12.

PMID:
9126321
15.

Importance and difficulty of determining the cost of clinical research.

Stedman D, Zwelling LA.

Acad Med. 1996 Nov;71(11):1164-7.

PMID:
9217506
16.

Phorbol ester-induced down-regulation of topoisomerase II alpha mRNA in a human erythroleukemia cell line. Evidence for a post-transcriptional mechanism.

Loflin PT, Altschuler E, Hochhauser D, Hickson ID, Zwelling LA.

Biochem Pharmacol. 1996 Oct 11;52(7):1065-72.

PMID:
8831726
18.

Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor.

Abbruzzese JL, Madden T, Sugarman SM, Ellis AL, Loughlin S, Hess KR, Newman RA, Zwelling LA, Raber MN.

Clin Cancer Res. 1996 Sep;2(9):1489-97.

19.

Effect of transfection of a Drosophila topoisomerase II gene into a human brain tumour cell line intrinsically resistant to etoposide.

Asano T, Zwelling LA, An T, McWatters A, Herzog CE, Mayes J, Loughlin SM, Kleinerman ES.

Br J Cancer. 1996 Jun;73(11):1373-80.

20.

Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.

Asano T, An T, Zwelling LA, Takano H, Fojo AT, Kleinerman ES.

Oncol Res. 1996;8(3):101-10.

PMID:
8823806
21.

Strategic service quality management for health care.

Anderson EA, Zwelling LA.

Am J Med Qual. 1996 Spring;11(1):3-10. Review.

PMID:
8763215
23.

Measuring service quality at the University of Texas M.D. Anderson Cancer Center.

Anderson EA, Zwelling LA.

Int J Health Care Qual Assur. 1996;9(7):9-22.

PMID:
10162922
24.
25.

Biochemical pharmacology of penclomedine (NSC-338720).

Benvenuto JA, Hittelman WN, Zwelling LA, Plunkett W, Pandita TK, Farquhar D, Newman RA.

Biochem Pharmacol. 1995 Oct 12;50(8):1157-64.

PMID:
7488229
26.

Mechanism of action and antitumor activity of (S)-10-(2,6-dimethyl-4-pyridinyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7 H- pyridol[1,2,3-de]-[1,4]benzothiazine-6-carboxylic acid (WIN 58161).

Coughlin SA, Danz DW, Robinson RG, Klingbeil KM, Wentland MP, Corbett TH, Waud WR, Zwelling LA, Altschuler E, Bales E, et al.

Biochem Pharmacol. 1995 Jun 29;50(1):111-22.

PMID:
7605336
27.
28.

Molecular analysis of a potentially phorbol-regulatable region of the human topoisomerase II alpha gene promoter.

Loflin PT, Hochhauser D, Hickson ID, Morales F, Zwelling LA.

Biochem Biophys Res Commun. 1994 Apr 15;200(1):489-96.

PMID:
8166723
29.

Phorbol regulation of topoisomerases I and II in human leukemia cells. Studies in an additional cell pair sensitive or resistant to phorbol-induced differentiation.

Ellis AL, Altschuler E, Bales E, Hinds M, Mayes J, Soares L, Zipf TF, Zwelling LA.

Biochem Pharmacol. 1994 Jan 20;47(2):387-96.

PMID:
8304982
30.

Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia.

Kaufmann SH, Karp JE, Jones RJ, Miller CB, Schneider E, Zwelling LA, Cowan K, Wendel K, Burke PJ.

Blood. 1994 Jan 15;83(2):517-30.

PMID:
7904487
31.
32.

Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent.

Ellis AL, Nowak B, Plunkett W, Zwelling LA.

Cancer Chemother Pharmacol. 1994;34(3):249-56.

PMID:
8004759
34.

Activity of two novel anthracene-9,10-diones against human leukemia cells containing intercalator-sensitive or -resistant forms of topoisomerase II.

Zwelling LA, Mayes J, Altschuler E, Satitpunwaycha P, Tritton TR, Hacker MP.

Biochem Pharmacol. 1993 Jul 20;46(2):265-71.

PMID:
8394077
35.

Consequences of the resistance to drug-induced topoisomerase II-mediated DNA cleavage.

Zwelling LA.

Toxicol Lett. 1993 Apr;67(1-3):231-6. Review.

PMID:
8383886
36.

Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cells.

Danks MK, Warmoth MR, Friche E, Granzen B, Bugg BY, Harker WG, Zwelling LA, Futscher BW, Suttle DP, Beck WT.

Cancer Res. 1993 Mar 15;53(6):1373-9.

38.

Components of intrinsic drug resistance in the rat hepatoma.

Ellis AL, Munger CE, Bunch RT, Woods KE, Randolph JK, Boise L, Swerdlow PS, Zwelling LA, Hinds M, Yanovich S, et al.

Biochem Pharmacol. 1992 Jan 22;43(2):331-42.

PMID:
1310853
41.

Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II.

Hinds M, Deisseroth K, Mayes J, Altschuler E, Jansen R, Ledley FD, Zwelling LA.

Cancer Res. 1991 Sep 1;51(17):4729-31.

42.

Cross-resistance of an amsacrine-resistant human leukemia line to topoisomerase II reactive DNA intercalating agents. Evidence for two topoisomerase II directed drug actions.

Zwelling LA, Mayes J, Hinds M, Chan D, Altschuler E, Carroll B, Parker E, Deisseroth K, Radcliffe A, Seligman M, et al.

Biochemistry. 1991 Apr 23;30(16):4048-55.

PMID:
1850298
43.

A lack of detectable modification of topoisomerase II activity in a series of human tumor cell lines expressing only low levels of etoposide resistance.

Hill BT, Whelan RD, Hosking LK, Shellard SA, Hinds MD, Mayes J, Zwelling LA.

Int J Cancer. 1991 Apr 1;47(6):899-902.

PMID:
1849124
44.

Effect of bryostatin 1 on drug-induced, topoisomerase II-mediated DNA cleavage and topoisomerase II gene expression in human leukemia cells.

Zwelling LA, Chan D, Altschuler E, Mayes J, Hinds J, Pettit GR.

Biochem Pharmacol. 1991 Mar 1;41(5):829-32.

PMID:
1847817
45.

The effect of staurosporine on drug-induced, topoisomerase II-mediated DNA cleavage in human leukemia cells.

Zwelling LA, Altschuler E, Mayes J, Hinds M, Chan D.

Cancer Chemother Pharmacol. 1991;29(1):48-52.

PMID:
1660353
46.
47.

HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug-sensitive topoisomerase II.

Zwelling LA, Slovak ML, Doroshow JH, Hinds M, Chan D, Parker E, Mayes J, Sie KL, Meltzer PS, Trent JM.

J Natl Cancer Inst. 1990 Oct 3;82(19):1553-61.

PMID:
1976136
48.

Enhancement of murine tumor cell sensitivity to adriamycin by presentation of the drug in phosphatidylcholine-phosphatidylserine liposomes.

Fan D, Bucana CD, O'Brian CA, Zwelling LA, Seid C, Fidler IJ.

Cancer Res. 1990 Jun 15;50(12):3619-26.

50.

Liblomycin-mediated DNA cleavage in human head and neck squamous carcinoma cells and purified DNA.

Wassermann K, Zwelling LA, Lown JW, Hartley JA, Nishikawa K, Lin JR, Newman RA.

Cancer Res. 1990 Mar 15;50(6):1732-7.

Supplemental Content

Loading ...
Support Center